PET-Adapted Treatment for Hodgkin Lymphoma

The highest PET score following three cycles of induction chemotherapy was associated with poor outcomes in patients with early-stage disease.

Standardized scoring of PET-based interim treatment response is predictive of ultimate remission and cure in Hodgkin lymphoma (HL). The prior retrospective, phase III RAPID trial (NEJM JW Oncol Hematol Jun 2015 and N Engl J Med 2015; 372:1598) showed that with the use of strict, centrally reviewed PET-imaging criteria for response-adapted treatment, 9 of 10 patients with early-stage HL were spared additional chemotherapy or radiotherapy after three cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

Investigators have now performed a secondary analysis of the RAPID study to assess the predictive value of the 5-point PET scoring system that was applied to risk-adapt therapy after three cycles of ABVD in 571 patients with ne…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

PET-Adapted Treatment for Hodgkin Lymphoma

Topics

Reviewing Author